Pemphigus Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 Pemphigus Vulgaris, an autoimmune blistering disease primarily affecting the skin and mucous membranes, is characterized by circulating autoantibodies directed against keratinocyte cell surfaces. The root cause of Pemphigus Vulgaris lies in these autoantibodies, which specifically target keratinocyte proteins known as desmogleins. This attack leads to an adhesion breakdown between keratinocytes, a phenomenon called acantholysis. This destructive process is initiated by binding circulating immunoglobulin G (IgG) autoantibodies to intercellular adhesion molecules. Pemphigus Vulgaris can manifest at any age, though it is most commonly diagnosed in individuals aged 45 to 65. In a typical presentation of Pemphigus Vulgaris, approximately 80% of cases start with lesions on the oral mucosa, often resulting in blister formation that can rupture and cause painful erosions. Cutaneous lesions occur in about 75% of patients, typically following the development of oral blisters. The disease can also cause vesicles, erosions, or bullae on skin that may appear red or normal. A characteristic sign of Pemphigus Vulgaris is the Nikolsky sign, where blisters form with minimal pressure or trauma. The primary treatment approach for Pemphigus Vulgaris involves systemic corticosteroids, supplemented with other immunosuppressant drugs like azathioprine or mycophenolate mofetil (MMF). These medications are usually administered orally or via intravenous infusion. Secondary treatments such as plasmapheresis and rituximab may be employed in some instances. Beyond pharmacological interventions, physical therapy can be beneficial in helping Pemphigus Vulgaris patients manage their symptoms and enhance their overall quality of life.

 

Thelansis’s “Pemphigus Vulgaris Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pemphigus Vulgaris treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Pemphigus Vulgaris across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Pemphigus Vulgaris Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Pemphigus Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Pemphigus Vulgaris, Pemphigus Vulgaris market outlook, Pemphigus Vulgaris competitive landscape, Pemphigus Vulgaris market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)